Zobrazeno 1 - 10
of 362
pro vyhledávání: '"Beth A, Christian"'
Autor:
Cushman, Ellen
Publikováno v:
Studies in Second Language Acquisition, 2007 Sep 01. 29(3), 489-491.
Externí odkaz:
https://www.jstor.org/stable/44487170
Autor:
Vine, Elaine W.
Publikováno v:
Discourse Studies, 2006 Apr 01. 8(2), 328-329.
Externí odkaz:
https://www.jstor.org/stable/24048991
Publikováno v:
Supplementum Epigraphicum Graecum / Supplementum Epigraphicum Graecum
Externí odkaz:
http://dx.doi.org/10.1163/1874-6772_seg_a64_1808
Autor:
Ellen Cushman
Publikováno v:
Studies in Second Language Acquisition. 29
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2422e0e91a71c0240a564e19c2e2342d
https://doi.org/10.1017/s0272263107070313
https://doi.org/10.1017/s0272263107070313
The authors present a social linguistic/social interactional approach to the discourse analysis of classroom language and literacy events. Building on recent theories in interactional sociolinguistics, literary theory, social anthropology, critical d
Autor:
David A. Bond, Ying Huang, Beth A. Christian, Samantha Jaglowski, Don Benson, Lapo Alinari, Robert A. Baiocchi, Jonathon B. Cohen, Kristie A. Blum, Kami J. Maddocks
Publikováno v:
Leukemia & Lymphoma. 63:1750-1753
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c7e2604e18b3b362d8147e751559167e
https://doi.org/10.1080/10428194.2022.2034154
https://doi.org/10.1080/10428194.2022.2034154
Autor:
Walter Hanel, Polina Shindiapina, David A. Bond, Yazeed Sawalha, Narendranath Epperla, Timothy Voorhees, Rina Li Welkie, Ying Huang, Gregory K. Behbehani, Xiaoli Zhang, Eric McLaughlin, Wing K. Chan, Jonathan E. Brammer, Samantha Jaglowski, John C. Reneau, Beth A. Christian, Basem M. William, Jonathon B. Cohen, Robert A. Baiocchi, Kami Maddocks, Kristie A. Blum, Lapo Alinari
Publikováno v:
Cancers
Volume 15
Issue 5
Pages: 1437
Volume 15
Issue 5
Pages: 1437
Background: Relapsed or refractory classical Hodgkin lymphoma (cHL) remains a difficult treatment challenge. Although checkpoint inhibitors (CPI) have provided clinical benefit for these patients, responses are generally not durable, and progression
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2573fe5d1a45884763781762414b4c49
https://doi.org/10.3390/cancers15051437
https://doi.org/10.3390/cancers15051437
Autor:
Lisa Brown, Ann S. LaCasce, Linda Ho, Beth A. Christian, Chiyu Zhang, Nancy L. Bartlett, Ranjana H. Advani, Alex F. Herrera, Sahar Ansari, David R. Taft, Mariana Sacchi, Tatyana Feldman, Alison J. Moskowitz, Stephen M. Ansell, Julie M. Vose, Craig H. Moskowitz, Radhakrishnan Ramchandren
Publikováno v:
Blood. 138(6)
This phase 1-2 study evaluated brentuximab vedotin (BV) combined with nivolumab (Nivo) as first salvage therapy in patients with relapsed/refractory (r/r) classical Hodgkin lymphoma (cHL). In parts 1 and 2, patients received staggered dosing of BV an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d15b0eafd5b59fffb7b5f819a434b4bc
https://pubmed.ncbi.nlm.nih.gov/34383039
https://pubmed.ncbi.nlm.nih.gov/34383039
Autor:
Arwa Shana'ah, Beth A. Christian, Jennifer A. Woyach, Kami J. Maddocks, Dan Jones, Narendranath Epperla, Sabarish Ayyappan
Publikováno v:
Blood Advances. 3:500-502
Ibrutinib is approved by the US Food and Drug Administration for the treatment of patients with relapsed/refractory marginal zone lymphoma (MZL) who are progressing on at least 1 previous anti-CD20–based therapy. This approval was based on the resu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36a9cb49680357d2b4a1c1c23be25ee0
https://doi.org/10.1182/bloodadvances.2018029058
https://doi.org/10.1182/bloodadvances.2018029058
Autor:
Kimberly Davies, Michael E. Williams, William Martin-Doyle, Jakub Svoboda, Zhengming Chen, Beth A. Christian, Catherine M. Bollard, Ann S. LaCasce, James Godfrey, Matthew J. Barth, Rebecca Gardner, Jody Sima, Matthew J. Oberley, Kristie A. Blum, Amanda M. Termuhlen, John P. Leonard, Tara O'Donohue, Sheila Weitzman, Zeinab Afify, Burton Appel, Christopher J. Forlenza, Hema Dave, Jennifer Levine, Carla Casulo, Deborah M. Stephens, Benjamin Mizukawa, Nancy L. Bartlett, Sonali M. Smith, Melinda Pauly, Sarah Alexander, Lisa Giulino-Roth, William A. Zeitler
Publikováno v:
British Journal of Haematology. 179:739-747
Summary Treatment with dose-adjusted EPOCH (etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone) chemotherapy and rituximab (DA-EPOCH-R) has become the standard of care for primary mediastinal B-cell lymphoma (PMBCL) at many institution
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c5f7e95f98963ab8d14ef1ebb978bd9b
https://doi.org/10.1111/bjh.14951
https://doi.org/10.1111/bjh.14951